Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIMABOTULINUMTOXINB vs RISANKIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIMABOTULINUMTOXINB vs RISANKIZUMAB: Safety Overview

Metric RIMABOTULINUMTOXINB RISANKIZUMAB
Total FAERS Reports 176 2,642
Deaths Reported 38 41
Death Rate 21.6% 1.6%
Hospitalizations 35 439
Average Patient Age 59.0 yrs 52.1 yrs
% Female Patients 68.6% 51.3%
Manufacturer Solstice Neurosciences, LLC AbbVie Inc.
Route INTRAMUSCULAR SUBCUTANEOUS